Drugs / Palbociclib
Palbociclib
Drug FDA approvedMarketed as Ibrance
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor·First approved·2015·1 brand
- Registered trials
- 244
- Ongoing
- 104/ 43%
- Completed
- 89
- Indications
- 2
Approved indications by brand
| Brand | Indication |
|---|---|
| Ibrance | "HR-positive |
| HER2-negative advanced or metastatic breast cancer (with aromatase inhibitor or fulvestrant)" |
Clinical trial landscape
244 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 96 | 41 | 35 | |
| Phase 1 | 54 | 19 | 23 | |
| Phase 1/2 | 31 | 17 | 6 | |
| Unknown | 26 | 6 | 15 | |
| Phase 3 | 23 | 16 | 6 | |
| Early Phase 1 | 5 | 1 | 2 | |
| Not applicable | 4 | 2 | 0 | |
| Phase 4 | 3 | 1 | 1 | |
| Phase 2/3 | 2 | 1 | 1 | |
| All phases | 244 | 104 | 89 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Cyclin-dependent kinase 4/6 (CDK4/6) inhibition.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.